Angelin Mary Philip

Dr. Angelin Mary Philip

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Open access
WAWesam S. Ahmed
Wesam S. Ahmed
AGAnupriya M. Geethakumari
Anupriya M. Geethakumari
ASAsfia Sultana
Asfia Sultana
AFAsma Fatima
Asma Fatima
APAngelin Mary Philip
Angelin Mary Philip
KBKabir H Biswas
Kabir H Biswas
NanoLuc (NLuc) luciferase has found extensive application in designing a range of biological assays, including gene expression analysis, protein-protein interaction, and protein conformational changes due to its enhanced brightness and small size. However, questions related to its mechanism of interaction with the substrate, furimazine, as well as bioluminescence activity remain elusive. Here, we combined molecular dynamics (MD) simulation and mutational analysis to show that the R162A mutation results in a decreased but stable bioluminescence activity of NLuc in living cells and in vitro. Specifically, we performed multiple, all-atom, explicit solvent MD simulations of the apo and furimazine-docked (holo) NLuc structures revealing differential dynamics of the protein in the absence and presence of the ligand. Further, analysis of trajectories for hydrogen bonds (H-bonds) formed between NLuc and furimazine revealed substantial H-bond interaction between R162 and Q32 residues. Mutation of the two residues in NLuc revealed a decreased but stable activity of the R162A, but not Q32A, mutant NLuc in live cell and in vitro assays performed using lysates prepared from cells expressing the proteins and with furimazine substrate. In addition to highlighting the role of the R162 residue in NLuc activity, we believe that the mutant NLuc will find wide application in designing in vitro assays requiring extended monitoring of NLuc bioluminescence activity. SIGNIFICANCE: Bioluminescence has been extensively utilized in developing a variety of biological and biomedical assays. In this regard, engineering of brighter bioluminescent proteins, i.e. luciferases, has played a significant role. This is acutely exemplified by the engineering of the NLuc luciferase, which is small in size and displays much enhanced bioluminescence and thermal stability compared to previously available luciferases. While enhanced bioluminescent activity is desirable in a multitude of biological and biomedical assays, it would also be useful to develop variants of the protein that display a prolonged bioluminescence activity. This is specifically relevant in designing assays that require bioluminescence for extended periods, such as in the case of biosensors designed for monitoring slow enzymatic or cellular signaling reactions, without necessitating multiple rounds of luciferase substrate addition or any specialized reagents that result in increased assay costs. In the current manuscript, we report a mutant NLuc that possesses a stable and prolonged bioluminescence activity, albeit lower than the wild-type NLuc, and envisage a wider application of the mutant NLuc in designing biosensors for monitoring slower biological and biomedical events.

Verified
Journal Article
Open access
PDF file
APAngelin Mary Philip
Angelin Mary Philip
SUS M NASIR UDDIN
S M NASIR UDDIN
ZEYAUL ISLAMZEYAUL ISLAM
ZEYAUL ISLAM
PKPrasanna Kolatkar
Prasanna Kolatkar
KBKabir H Biswas
Kabir H Biswas
The SARS-CoV-2 spike protein, through its receptor binding domain (S1-RBD), binds to the angiotensin-converting enzyme 2 (ACE2) receptor on the host cell membrane, leading to viral infection. Several mutations in S1-RBD in SARS-CoV-2 variants are known to enhance infection through an increased affinity for ACE2. While many reports are available describing the SARS-CoV-2 infection mechanism, there is a dearth of studies towards understanding the initial interaction of the S1-RBD with ACE2 on living host cells and the role of endocytosis and cytoskeleton in the process. Here, we reconstituted the interaction between S1-RBD- and ACE2-expressing host cells in a hybrid live cell-supported lipid bilayer (SLB) platform enabling live monitoring of the interaction between S1-RBD on SLBs and the ACE2 receptor on living cells and showed that cells depleted Omicron S1-RBD from SLB corrals, likely through endocytosis. Specifically, interaction of living host cells with S1-RBD-functionalized SLB substrates resulted in the enrichment of S1-RBD and ACE2 at the cell–SLB interface. Interaction of host cells with wild type (WT), Omicron, and Omicron Revertant S1-RBD functionalized on micron-scale SLB corrals, which mimic viral membranes but are flat, also resulted in their enrichment. However, cells interacting with Omicron S1-RBD revealed a depletion of the protein from many corrals, which was generally not observed with the WT S1-RBD and was reduced with the Omicron Revertant, which contains the Q493R mutation reversion, S1-RBD. Further, S1-RBD depletion coincided with the localization of the early endosomal marker EEA1. Importantly, treatment of cells with the clathrin inhibitor, pitstop 2, but not the myosin II inhibitor, blebbistatin, significantly reduced Omicron S1-RBD depletion. Collectively, these observations suggest that the SARS-CoV-2 Omicron variant has evolved, through mutations in its S1-RBD, to take advantage of the cellular endocytic pathway for enhanced infection, which is not observed with the parental SARS-CoV-2 and appears to be lost in the Omicron Revertant variant. Additionally, these results underscore the significance of the hybrid live cell–SLB platform in studying SARS-CoV-2 S1-RBD-ACE2 interaction and the potential impact of mutations in the S1-RBD on adapting to a specific cellular entry mechanism.

23 May 2026 in Biosensors and Bioelectronics
Verified
Journal Article
Open access
AFAsma Fatima
Asma Fatima
AGAnupriya M. Geethakumari
Anupriya M. Geethakumari
SUS.M. Nasir Uddin
S.M. Nasir Uddin
APAngelin Mary Philip
Angelin Mary Philip
ASAsfia Sultana
Asfia Sultana
KBKabir H Biswas
Kabir H Biswas
The main protease (Mpro) and the papain-like protease (PLpro) are critical for SARS-CoV-2 replication due to their roles in proteolytic processing of viral pp1a and pp1ab polyproteins into functional proteins. While the two proteases and their cleavage sites have been studied extensively, a comprehensive understanding of their cleavage kinetics and inhibitor potency in living cells is lacking in the literature. Here, we report the engineering of a two-color Bioluminescence Resonance Energy Transfer (BRET)-based, dual protease biosensor (DuProSense) platform that revealed differential cleavage kinetics and inhibitor potency of SARS-CoV-2 proteases. Briefly, we incorporated two spectrally distinct fluorescent acceptor proteins, along with SARS-CoV-2 protease cleavage peptides at the N- and C-termini of a BRET donor luciferase protein for simultaneous, highly specific monitoring of two proteolytic cleavage events. Live-cell experiments with DuProSense revealed similar Mpro and PLpro cleavage kinetics for their N-terminal autocleavage sites. Importantly, systematic characterization of all Mpro and PLpro cleavage sites individually using the DuProSense platform revealed significant differences in their cleavage rates. Further, in vitro assays using purified Mpro cleavage-site-containing DuProSense biosensors revealed significant differences in their catalytic processing by Mpro. Additionally, Mpro cleavage-site-containing DuProSense biosensors revealed Mpro cleavage-site-specific nirmatrelvir potency, which did not correlate with their cleavage rates in living cells. Overall, the DuProSense platform developed here provided deeper insights into SARS-CoV-2 polyprotein processing and will find wider applications that require simultaneous monitoring of two proteolytic events.